Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Citius Oncology, Inc. (CTOR)
USD0.66
+0.01 (+1.31%)
US NASDAQ Healthcare Drug Manufacturers - General
Address
420 Lexington Avenue 10170
New York City, NY, US
New York City, NY, US
CEO
Leonard L. Mazur
IPO
2022-12-08
CIK 1851484 ISIN US17331Y1091
Description
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.66
+0.01 (+1.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
90.0K
Beta
3.42
Float Shares
4.75M
Free Float %
5.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.13% | +9.47% | +9.73% | -18.36% | -21.04% | -3.67% | +5.86% | -91.57% | -91.57% | -91.57% | -91.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.66
Low
6.00
+811.2%
Consensus
6.00
+811.2%
Median
6.00
+811.2%
High
6.00
+811.2%
DCF (Unlevered)
0.10
-84.2%
DCF (Levered)
0.00
-99.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
6.00
+811.2%
|
| All Time | 1 |
6.00
+811.2%
|
Quality scores
Altman Z-Score
-2.28
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%—
-
EPS growth Drug Manufacturers - General: +18.2%-13.3% Q1'26: -145.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%— Q1'26: -238.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%— Q1'26: -1,716.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%-52.5% Q1'26: -311.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+2.4% Q1'26: +39.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×-0.16× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 28.68M (-100.0%)
|
38.87M
38.87M – 38.87M
+35.5% YoY
|
118.95M
118.95M – 118.95M
+206.0% YoY
|
157.41M
157.41M – 157.41M
+32.3% YoY
|
177.01M
177.01M – 177.01M
+12.5% YoY
|
196.30M
196.30M – 196.30M
+10.9% YoY
|
| EBITDA |
-20.57M
|
-23.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-20.57M
|
-23.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-21.15M
est: -20.75M (-1.9%)
|
-24.76M
est: -24.18M (-2.4%)
|
-11.72M
-11.72M – -11.72M
+51.5% YoY
|
28.57M
28.57M – 28.57M
+343.8% YoY
|
54.95M
54.95M – 54.95M
+92.3% YoY
|
62.28M
62.28M – 62.28M
+13.3% YoY
|
69.60M
69.60M – 69.60M
+11.8% YoY
|
| SGA |
15.65M
|
17.10M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.30
est: -0.29 (-3.4%)
|
-0.34
est: -0.33 (-3.0%)
|
-0.16
-0.16 – -0.16
+51.5% YoY
|
0.39
0.39 – 0.39
+343.8% YoY
|
0.75
0.75 – 0.75
+92.3% YoY
|
0.85
0.85 – 0.85
+13.3% YoY
|
0.95
0.95 – 0.95
+11.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 137.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 625.73 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 1.7K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 126.90 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 293.7K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 643.79 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 350.23 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 141.58 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 15.59 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 2.20 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
7.00
Bullish
Buys
7
Sells
1
Shares acquired
3.12M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+3,116,667
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-19 | Webb Carol | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | D | ↗ |
| 2025-09-19 | Smith Robert Joseph | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | D | ↗ |
| 2025-09-19 | Mazur Leonard L | Director / Officer | A-Award | A | Common Stock | 1,700,000 | 0.00 | — | 1,700,000 | D | ↗ |
| 2025-09-19 | Mayersohn Joel David | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 321,228 | D | ↗ |
| 2025-09-19 | MCGRATH DENNIS M | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | D | ↗ |
| 2025-09-19 | Holuka Eugene Myron | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | D | ↗ |
| 2025-09-19 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Common Stock | 850,000 | 0.00 | — | 850,000 | D | ↗ |
| 2025-09-19 | Dutia Suren G | Director | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | D | ↗ |
| 2025-09-19 | Czuczman Myron | Officer | A-Award | A | Common Stock | 825,000 | 0.00 | — | 825,000 | D | ↗ |
| 2025-09-19 | Bartushak Jaime | Officer | A-Award | A | Common Stock | 825,000 | 0.00 | — | 825,000 | D | ↗ |
| 2025-07-28 | Mayersohn Joel David | Director | J-Other | A | Common Stock | 21,228 | 0.00 | — | 21,228 | D | ↗ |
| 2024-12-12 | Webb Carol | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.07 | 133.8K | 125,000 | D | ↗ |
| 2024-12-12 | Smith Robert Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.07 | 133.8K | 125,000 | D | ↗ |
| 2024-12-12 | Mazur Leonard L | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 1.07 | 856.0K | 800,000 | D | ↗ |
| 2024-12-12 | Mayersohn Joel David | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 1.07 | 267.5K | 250,000 | D | ↗ |
| 2024-12-12 | MCGRATH DENNIS M | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.07 | 133.8K | 125,000 | D | ↗ |
| 2024-12-12 | Holuka Eugene Myron | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.07 | 133.8K | 125,000 | D | ↗ |
| 2024-12-12 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 1.07 | 321.0K | 300,000 | D | ↗ |
| 2024-12-12 | Dutia Suren G | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.07 | 133.8K | 125,000 | D | ↗ |
| 2024-12-12 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.07 | 428.0K | 400,000 | D | ↗ |
| 2024-12-12 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.07 | 428.0K | 400,000 | D | ↗ |
| 2024-08-12 | Webb Carol | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.15 | 322.5K | 150,000 | — | ↗ |
| 2024-08-12 | Smith Robert Joseph | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | Mazur Leonard L | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | MCGRATH DENNIS M | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.15 | 322.5K | 150,000 | — | ↗ |
| 2024-08-12 | Holuka Eugene Myron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | HOLUBIAK MYRON Z | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | Dutia Suren G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | Czuczman Myron | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | Citius Pharmaceuticals, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 65,627,262 | — | ↗ |
| 2024-08-12 | Bartushak Jaime | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
88.28M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Myron Z. Holubiak | Executive Vice Chairman & Secretary | 450.0K | male |
| Myron S. Czuczman | Executive Vice President & Chief Medical Officer | 225.0K | — |
| Leonard L. Mazur | Chief Executive Officer, President & Executive Chairman | 166.3K | male |
| Jaime Bartushak | Chief Financial Officer & Treasurer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTOR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
